Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. - Wikidata - awgldk - TriplyDB

Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

http://www.wikidata.org/entity/Q34679345

about

Interventions for preventing neuropathy caused by cisplatin and related compounds The Use of Calcium and Magnesium to Prevent Neurotoxicity in Patients Receiving Oxaliplatin Mechanisms of chemotherapy-induced behavioral toxicities Chemotherapy-induced peripheral neurotoxicity: a critical analysis Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors Efficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysis [EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?Predicting acute and persistent neuropathy associated with oxaliplatin.Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab.Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: A meta-analysis.A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.Platinum-induced neurotoxicity and preventive strategies: past, present, and future α7 Nicotinic Receptor Promotes the Neuroprotective Functions of Astrocytes against Oxaliplatin Neurotoxicity New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment.Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.Impact of oxaliplatin-induced neuropathy in patients with colorectal cancer: a prospective evaluation at a single institution.Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.Self-management of oxaliplatin-related peripheral neuropathy in colorectal cancer survivors Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX Clinical study on the prevention of oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo-controlled trial.National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.The search for treatments to reduce chemotherapy-induced peripheral neuropathy.Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).Chemotherapy-induced peripheral neuropathy: prevention and treatment.Oxaliplatin: a review of approved uses.Occupational exposure to municipal solid wastes and development of toxic neuropathies: possible role of nutrient supplementation, complementary and alternative medicines in chemoprevention.

P2860

Q24197763-0AE79653-4A9D-400F-9392-38AD461D1C55 Q26777881-3D3C40D3-7A45-4D5A-A5D4-0788868A1F0F Q26998870-7406A019-B743-465B-B607-AC4459BCBC45 Q27010318-629675E0-255A-4D10-9B38-C39A4B4FE8B8 Q30234847-7A1D36AF-4D23-4693-9316-F9E90CC7F76E Q30315797-84365CA7-CEEA-4CA7-81E0-882C56B8401B Q33693343-5BDFC592-B4F1-4EA3-9F76-B10FCBF2ACE8 Q33774892-4DA8B2CC-030F-4CFD-B0B0-A52B3C7F75A8 Q33824948-18742422-C090-4E84-9A3A-3D396357607B Q33841734-D3C02A37-BB35-403B-8BDD-C6B698D887C7 Q33868520-AAA04DB8-E23D-43E0-8565-7614819443E9 Q33889319-802E2093-A881-4F4F-8B84-2075B66F948F Q34049929-67960E0E-C550-48A6-B8E2-03FCD1990319 Q34194773-6CA432FC-CC9C-4000-8B42-F3A77306E06E Q34396212-57272A73-A1BE-409E-A456-FB3500F48891 Q34458581-4E51F0A6-76DA-4C94-9167-D9726B7FDF0C Q34506789-8654CA4E-AE2E-44BE-9E75-D6976C5DE6BA Q34619839-FBD54284-5E65-483D-B61A-299EA5BF90F0 Q34627846-A7133AC3-E21A-41E2-8D66-105759E6D974 Q34725699-15ABA756-7482-4645-9599-9882595E34F9 Q35025710-2EFFCCA1-07C7-4E21-9025-F8F99D283EE3 Q35345734-24FACBB9-A850-4303-B8FE-526E586A4E51 Q35749490-104F83B2-761A-4BB4-B62F-73A31B582177 Q36226275-E69CF69F-1888-483C-A476-B921FC4FF72D Q36329774-55D26DBF-5B13-427F-BB1C-A762CC055B72 Q36530731-BADC7E35-1498-4622-A260-E0FA9C81163A Q36581502-0DF0C8C6-ECDC-455F-B59A-51AA21D86B3F Q36618130-CE8EBFAF-FB1C-464B-A515-AB0FF262171A Q37031281-7BCB61A9-E27B-436F-9748-11CC04AC808B Q37082272-B3D4E466-527B-47AB-9C0F-37CCD300F15B Q37155944-4AF4B34D-A713-47AD-9CF0-954D94307235 Q37244795-1FCCDE6F-529F-466D-9A0C-895BE4C8EAD4 Q37353630-CD8C7299-6672-4D20-98BD-5D6ABDD8AEE6 Q37364316-2A103766-E82F-4CF8-891F-C99EEFA5D265 Q37410573-095D9875-A037-46F8-8FFB-C353D57FCA0D Q37410650-212B02A1-0C9D-43F8-8368-3ED35D9C681C Q37662241-15004243-8845-47B6-9223-A70101BC486A Q37911252-30F1710B-569C-4283-AD34-BA452A25332D Q37965616-0AEE8D03-A0E5-4551-A0D0-E85D74DAD6A3 Q38217325-1074F8D4-0C26-4FAD-A969-728F9953A175

P2860

Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

http://www.wikidata.org/entity/Q34679345

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@ast

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@en

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@nl

type

label

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@ast

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@en

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@nl

prefLabel

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@ast

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@en

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@nl

P1433

Q34679345-1FEB61BE-C81D-4143-B94B-8693D6B6F89E

P1476

Q34679345-66BB1134-296F-471D-A789-9577E4F7E2D4

P2093

Q34679345-0FA9137A-3CB4-4CE0-940F-6D078F1A262B

Q34679345-3574D8A3-14E7-41C6-8F0E-D52B3F67F61A

Q34679345-54FC5155-63A7-4538-B372-41C8E8497F48

Q34679345-600FDFA4-0887-4FA3-B48F-EF34DC1B4F19

Q34679345-67EA4BA4-13A7-4551-A669-C88D69F8376E

Q34679345-9B409FEB-C448-41D3-B1E2-0870F9022BC7

Q34679345-A607167E-6DDF-42A9-AC87-4A3DF8075865

Q34679345-A99B37F1-4B95-45E4-BC92-8E9C7AF38C39

Q34679345-AE18EC72-8F78-486E-A347-F99ABF6A4B73

Q34679345-B989EC74-CC87-4396-8CBB-5931BC40255D

P2860

Q34679345-12D628D6-58CF-4350-B125-F00ADFE2E33C

Q34679345-217AA63A-AE4F-4B81-A480-98E56176B96E

Q34679345-44248C56-62DF-4EF9-9800-CE59E44E2D94

Q34679345-49C43F54-AA41-4568-8B89-E37EE85CABB3

Q34679345-5F7A01E7-D6D6-4D68-A272-CF1C895E73CD

Q34679345-6201CD6B-60F9-4C2C-80DA-E2EF710EBB1C

Q34679345-68FA9347-13D3-4FB1-815A-30FB43C36D7A

Q34679345-7DFC1FB2-D5E3-4A55-B20B-B877C9A72F92

Q34679345-8A56DEF0-0DE7-434B-9CCC-73CE1AD20E53

Q34679345-DAAB9CD1-92AC-4515-9078-57689B69B344

P304

Q34679345-20A5BBC8-8E64-4B25-B343-C09727CCC4D7

P31

Q34679345-E768AF60-33D8-4C88-8FD1-4CB0ADFF6E59

P356

Q34679345-FDBA22C1-1BF5-4572-B2FA-58977AB0BF12

P407

Q34679345-1D1EF57D-6AE2-459C-9D8A-8463271D40AD

P433

Q34679345-26951EFF-AAE8-4AB3-955B-970EA80E070B

P478

Q34679345-C436EEC2-50D8-4D27-805E-408E4FBB9767

P577

Q34679345-290227B8-4FFA-4D10-9156-14B5BAC6E289

P5875

Q34679345-29038E4E-A901-4B81-8EAD-9FCFABA8F1AB

P698

Q34679345-68C7AAAB-5142-4AF7-A994-8F0D2B174C22

P921

Q34679345-12DBDEB0-44C8-4236-9C4B-0C8F7A791199

Q34679345-4fcfec81-070f-4521-b173-259da15b5e01

P932

Q34679345-99CAC96C-88FC-4571-9F04-0EC3AC104FE6

P356

JCO.2010.31.5911

P1433

Journal of Clinical Oncology

P1476

Intravenous calcium and magnes ...... ant colon cancer: NCCTG N04C7.

@en

P2093

Axel Grothey

http://www.w3.org/2001/XMLSchema#string

Charles L Loprinzi

http://www.w3.org/2001/XMLSchema#string

Daniel A Nikcevich

http://www.w3.org/2001/XMLSchema#string

Donald B Wender

http://www.w3.org/2001/XMLSchema#string

Jeff A Sloan

http://www.w3.org/2001/XMLSchema#string

John W Kugler

http://www.w3.org/2001/XMLSchema#string

Paul J Novotny

http://www.w3.org/2001/XMLSchema#string

Peter T Silberstein

http://www.w3.org/2001/XMLSchema#string

Steven R Alberts

http://www.w3.org/2001/XMLSchema#string

Todor Dentchev

http://www.w3.org/2001/XMLSchema#string

P2860

Calcium block of Na+ channels and its effect on closing rate

Cisplatin and hypomagnesemia.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Oxaliplatin-safety profile: neurotoxicity.

Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks.

Acute oxaliplatin-induced peripheral nerve hyperexcitability.

Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.

Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.

P304

421-427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.31.5911

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49712769

http://www.w3.org/2001/XMLSchema#string

P698

21189381

http://www.w3.org/2001/XMLSchema#string

P921

Béésh Łikoní

P932

3058288

http://www.w3.org/2001/XMLSchema#string